Poor Science; Poorly Trained Scientists; Poor Policies: Major Deterrents to the War on Cancer
- Authors
-
-
Leslie C. Costello
School of Dentistry Department of Oncology and Diagnostic Sciences and the Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, USA
-
- Keywords:
- Cancer, NIH policies, training of scientists, excessive molecular biology, holistic physiological/pathophysiological approach.
- Abstract
-
Although the availability of funding has been described as the major limitation on advances in cancer, the progress in the war on cancer has been deterred mainly by poor science, poorly trained scientists, and poor NIH policies. This is the result of NIH policies of its extreme focus on molecular biology (genomics, molecular genetics, molecular biology) identification of the molecular factors and pathways; which are required for the acceptability of treatment and preventive protocols. As such, this has influenced virtually all agencies that provide grants for medical research to adopt the NIH policies. This has impacted the funding of the research as well as the focus of the training of scientists. Directors of NCI Dr. Varmus (also Nobel Prize awardee) and Dr. Zerhouni had addressed this issue; and they rejected the necessity of molecular biology studies and information. NIH should return to the holistic physiological/pathophysiological approach to studies of cancer issues. This would provide the best approach for winning the war on cancer.
- Downloads
-
Download data is not yet available.
- References
-
Zerhouni E. The NIH roadmap. Science 2003; 332: 63-5. https://doi.org/10.1126/science.1091867
Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004; 149(6): 76-82.
Costello LC. The effect of contemporary education and training of biomedical scientists on present and future medical research. Acad Med 2009; 84: 459-63. https://doi.org/10.1097/ACM.0b013e31819a7c6b
Perspective: Is NIH funding the "best science by the best scientists"? A critique of the NIH R01 research grant review policies. Acad Med 2010; 85(5): 775-9. https://doi.org/10.1097/ACM.0b013e3181d74256
National Institutes of Health. Enhancing Peer Review at NIH: Overview. Available at: http://enhancing-peer-review.nih.gov/index.html. Accessed January 18, 2010
Office of Extramural Research, National Institutes of Health. Encouraging Early Transition to Research Independence: Modifying the NIH New Investigator Policy to Identify Early Stage Investigators. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-121.html. Accessed January 18, 2010.
Bernard C. An Introduction to the Study of Experimental Medicine. New York, NY: The Macmillan Company 1927.
- Downloads
- Published
- 15-08-2018
- Issue
- Vol. 7 No. 3 (2018)
- Section
- Articles
How to Cite
Similar Articles
- Belisario A. Arango, Bertha E. Sanchez, Matthew C. Abramowitz, Edgardo S. Santos, Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Sisir Nandi, Manish C. Bagchi, Exploring CDKs, Ras-ERK, and PI3K-Akt in Abnormal Signaling and Cancer , Journal of Cancer Research Updates: Vol. 11 (2022)
- Kenichi Suda, Simon Ito, Hiroshi Mizuuchi, Yoshihiko Maehara, Yasushi Yatabe, Tetsuya Mitsudomi, EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Vito Lorusso, Ilaria Marech, Marianna Giampaglia, Andrea Tinelli, Vincenzo Emanuele Chiuri, Present and Emerging Targeted Therapy for Metastatic Breast Cancer , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Guanghui Yang, Honglu Zhang, Glenn D. Prestwich, Tissue-Engineered “Metastases”: Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Brianna N. Harris, Uttam K. Sinha, Cancer Stem Cells: A Review of the Literature and the Implications in Head and Neck Cancer , Journal of Cancer Research Updates: Vol. 2 No. 3 (2013)
- Marwa Aboalsoud, Zeinab Fathy Abdallah, Rabab A. Moussa, Eman E. Farghal, Asmaa Mohamed Elkady, Bevacizumab in Advanced High Grade Serous Ovarian Cancer: The Impact of BRCA Mutation Status , Journal of Cancer Research Updates: Vol. 15 No. 1 (2026)
- Atish Patel, Hui Zhang, Deshen Wang, Dong-Hua Yang, Sanjay Dholakiya, Zhe-Sheng Chen1, Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML , Journal of Cancer Research Updates: Vol. 7 No. 2 (2018)
- G.R. Nivashini, Lalatendu Moharana, Ashish Jawarkar, Komal Parashar, Tarun Parashar, Dinesh Kumar Yadav, Targeting Inflammatory Pathways in Cancer: Novel Insights into Tumorigenesis and Personalized Therapeutic Approaches , Journal of Cancer Research Updates: Vol. 15 No. 1 (2026)
- Wei Zhang, Li-Wu Fu, ABC Transporters: Maintenance of the Cancer Stem Cell Phenotype , Journal of Cancer Research Updates: Vol. 3 No. 1 (2014)
You may also start an advanced similarity search for this article.